P
atients hospitalized for acutely decompensated heart failure (HF) commonly suffer functional decline, rehospitalization, and death. With the advent of financial penalties from the Centers for Medicare and Medicaid Services for excess 30-day readmissions, most US hospitals have instituted formal programs to reduce preventable rehospitalizations in patients with HF. 1 However, resulting declines in 30-day readmissions have plateaued, only 1/3 of readmissions are because of recurrent HF, and 30-day mortality has increased in recent years. 2, 3 Clearly, more effective strategies are needed to improve outcomes for patients with HF during the particularly vulnerable postdischarge period 4 and beyond. Dietary factors are thought to contribute to many HF hospitalizations, 5 and dietary recommendations for patients with HF historically have focused on sodium restriction. 6 Yet, this strategy has been associated with increased readmission rates and even mortality in several large clinical trials. 7, 8 One potential reason is that patients with HF instructed to eat less sodium may inadvertently worsen existing nutritional deficits. 9 In addition, patients with HF often face significant barriers to follow healthy eating patterns. 10 In light of these challenges, we conducted the GOUR-MET-HF pilot study (Geriatric Out-of-Hospital Randomized Meal Trial in Heart Failure). GOURMET-HF is the first trial to test the effects of home-delivered, nutritionally complete, sodium-restricted meals in patients after discharge from HF hospitalization. We hypothesized that this strategy would improve disease-specific quality of life at 4 weeks postdischarge. Given previous studies demonstrating adverse events with a low-sodium diet, important additional goals of GOURMET-HF were to assess the safety of the intervention, including effects on cardiac biomarkers and rehospitalization burden.
METHODS

Study Design and Population
The study design and methods of GOURMET-HF have previously been published. 11 The data, methods used in the analysis, and materials used to conduct the research will not be made available to other researchers. In brief, GOURMET-HF was a randomized, controlled trial of 12 weeks total duration conducted at 3 sites (Michigan Medicine/University of Michigan, Ann Arbor Veterans Affairs Health System, both in Ann Arbor, MI; and Columbia University Medical Center/New York Presbyterian Hospital, in New York, NY). The trial was approved by the institutional review board at each site, and all enrolled participants gave written informed consent.
Patients ≥65 years of age having primary hospitalization for acute decompensated HF and meeting no exclusion criteria at hospital discharge (Table 1) were randomized to usual care versus receiving 4 weeks of home-delivered meals. Because of slower-than-expected recruitment, the age of inclusion was later lowered to ≥55 years after discussion with National Institutes of Health/National Institute of Aging and the study Data and Safety Monitoring Board.
The primary outcome of GOURMET-HF was the intergroup change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score between discharge and 4 weeks postdischarge. 12 The study diet (sodium-restricted Dietary Approaches to Stop Hypertension meals [DASH/SRD]) followed the DASH pattern, recommended for patients with hypertension, 13 and was sodium-restricted to 1500 mg/d, as per American Heart Association recommendations. 14 Randomization was stratified by sex and by left ventricular ejection fraction <50% versus ≥50%. Investigators were blinded to treatment assignment. Participants were assessed in-person at hospital discharge and at 1, 4, and 12 weeks postdischarge, and their care was otherwise managed by their usual medical team.
Physical examinations, blood pressure measurements, and blood samples for renal function and electrolytes were performed at a safety visit 1 week postdischarge. At this visit, the investigator could adjust HF therapies as needed to maintain clinical stability or stop the dietary intervention if potentially diet-related adverse events occurred. These parameters were assessed again, along with the KCCQ, at the 4-week visit. In participants who were rehospitalized at the time of their 4-week visit, the KCCQ was administered as an inpatient. In patients who were unable to attend their 4-week visit, the KCCQ was obtained by mail.
WHAT IS NEW?
• Dietary factors are believed to be an important cause of hospitalizations in patients with heart failure (HF), but few dietary interventions have been performed in this population.
• Malnutrition is common in HF and associated with adverse outcomes, and the standard recommendation to restrict dietary sodium could contribute to dietary nutritional deficiencies.
• The GOURMET-HF pilot study (Geriatric Out-ofHospital Randomized Meal Trial in Heart Failure) is the first randomized trial to examine the effects of direct dietary support in patients with HF after hospital discharge.
WHAT ARE THE CLINICAL IMPLICATIONS?
• GOURMET-HF randomized patients with HF at hospital discharge to 4 weeks of home-delivered, low sodium, nutritionally complete meals versus usual care.
• Disease-specific quality of life (primary outcome) did not improve more in patients assigned to home-delivered meals.
• However, secondary analyses suggest potential benefits of this strategy on HF symptoms, physical limitations, and readmission reduction.
• Larger studies are warranted to clarify the effects of home-delivered meals on rehospitalization burden and quality of life in recently hospitalized patients with HF.
Intervention
The DASH/SRD contains higher intake of whole grains, fruits and vegetables, nuts and legumes, and lower intake of red meat and sweets than the typical American diet. 15 As recommended by the National Kidney Foundation, 16 the potassium content of the DASH/SRD in GOURMET-HF was reduced from 4500 mg/d to 3000 mg/d in patients with (1) discharge estimated glomerular filtration rate <45 mL/min per 1.73 m 2 , (2) discharge estimated glomerular filtration rate 45 to 60 and potassium >4.5 mmol/L, or (3) discharge potassium >4.5 mmol/L and potassium-sparing diuretic use.
Meals were prepared, packaged for refrigerator storage, and home-delivered once weekly by Mom's Meals NourishCare (PurFoods LLC, Ankeny, IA), a commercial entity. Each week participants assigned to the study diet could choose their preferred menu items from a variety of options tailored to DASH/ SRD specifications. Three daily meals, snacks, and some beverages were provided (see Data Supplement for sample menus) for a daily calorie intake of 2100. Both groups received a standardized educational pamphlet (see Data Supplement) at hospital discharge with information on how to follow a sodium-restricted diet (standard of care advice at the 3 study sites). Meal delivery was paused for rehospitalization and resumed at hospital discharge.
Study Outcomes
The KCCQ is a self-administered, 23-item instrument that assesses HF-related physical limitations, symptoms, self-efficacy, and social interference. The KCCQ summary score (primary outcome) and the individual KCCQ subdomain scores range from 0 to 100, with higher scores indicating better quality of life. We also evaluated intergroup change in the KCCQ clinical summary score, a composite of HF-related symptoms and physical limitations that is increasingly used as an end point in HF clinical trials. 17 Baseline dietary patterns and nutrient intake were assessed at hospital discharge using the 110-item Block Food Frequency Questionnaire as previously described. 18 Adherence to the study diet was assessed by meal delivery records from PurFoods and review of 3-day food diaries recorded during weeks 1 and 4 postdischarge. Overall adherence was defined as the proportion of the total meals consumed from the home-delivered study food. Cardiac biomarkers (high-sensitivity troponin I and BNP [B-type natriuretic peptide]), prealbumin, and C-reactive protein were measured at hospital discharge and at week 4. Twenty-four-hour urine collections were also performed for sodium and potassium excretion at these time points.
We identified symptomatic hypotension requiring urgent medical attention, hyperkalemia (serum potassium >5.7 mmol/L), and worsening renal insufficiency (defined as decrease in estimated glomerular filtration rate by >50%) as adverse events of special interest that could potentially be related to DASH/SRD. Readmissions, deaths, and the composite of postdischarge days hospitalized or dead through 12 weeks postdischarge were recorded for all participants.
Power Calculations and Statistical Analysis
Prestudy power calculations assumed an SD of the change in KCCQ summary score of 8 points and a 10% dropout rate. Based on a 2-sample t test, 66 randomized participants (33 per group) would provide >80% power to detect a 6-point difference between groups in the change in KCCQ summary score between discharge and week 4.
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All study outcomes were evaluated in an intent-to-treat analysis. Between-group differences in baseline characteristics were assessed using χ 2 tests for dichotomous variables and 2-sample t tests for continuous variables. Within-group discharge to week 4 changes in KCCQ summary scores were evaluated using paired t tests. Between-group comparisons were made using linear regression with week 4 KCCQ as the outcome and with treatment group and discharge KCCQ as covariates. The KCCQ clinical summary score, cardiac biomarkers, and other quantitative parameters were similarly evaluated, with log-transformation for B-type natriuretic peptide, high-sensitivity troponin I, and C-reactive protein because of skewed distribution. Missing data because of study withdrawals, missed visits, and death reduced the sample size for several of the tests.
The probabilities over time since discharge of all-cause rehospitalization and HF rehospitalization were visualized BNP indicates B-type natriuretic peptide; BP, blood pressure; eGFR, estimated glomerular filtration rate; and HF, heart failure.
using Kaplan-Meier curves, with between-group comparisons made using log-rank tests. The frequencies of potentially diet-related adverse events were compared between groups with Fisher exact test. Intergroup comparison of the number of days hospitalized or dead between the index discharge and 30 days postdischarge was performed using 2-sample t tests after log-x+1 transformation (ie, to avoid zero values, adding 1 to the number of days for scale of 1-31, then log-transforming). Data were analyzed using SAS software (Cary, NC).
RESULTS
A total of 107 patients were originally consented to participate in the study, and 66 were randomized 1:1 to DASH/SRD versus usual care at hospital discharge. The flow of participants through the study is shown in Figure 1 . The most common reasons for being consented but not randomized at hospital discharge were hypotension, hyperkalemia, and renal insufficiency during the index admission. Of the randomized participants, 6 (9%) did not complete the KCCQ primary outcome measure at week 4, 3 because of formal withdrawal from active participation, and 3 who did not attend the visit and declined to complete the questionnaire by mail. By week 12, 1 participant died, and 6 others withdrew from active participation in the study. All 66 randomized participants, including those who withdrew from active participation, were followed for 12 weeks by telephone and medical record review for rehospitalization or death.
Baseline characteristics of the study population are shown in Table 2 . In general, randomized participants were older adults, frequently were obese, and had multiple comorbid illnesses. Renal dysfunction, anemia, and elevated levels of BNP and high-sensitivity troponin I were common. The enrolled cohort was approximately one-third female and of diverse race and ethnicity. Most patients (64%) had left ventricular ejection fraction <50%. There were no significant between-group differences in baseline characteristics.
In available Food Frequency Questionnaire data (n=57 participants) obtained during the index hospitalization, estimated energy intake was 1602 (interquartile range, 1192-2154) kcal/d, sodium intake was 2987 (2148-3561) mg/d, and potassium intake 2557 (1911-3278) mg/d. There were no significant between-group differences in estimated calorie, sodium, or potassium intake. Energy and sodium intake were highly correlated (r=0.93; P<0.001).
Participants assigned to DASH/SRD received homedelivered meals for an average of 27±1 days postdischarge. Per review of 3-day food diaries, available in 29 of 33 participants assigned to DASH/SRD, 77% of all meals consumed consisted of complete or partial home-delivered study meals. Information on the nutrient content of study meals is shown in the Data Supplement. Compared with baseline intake, the study diet was ≈50% lower in sodium content while providing ≈25% more calories and a ≈25% to 45% increase in potassium content. Medication changes between hospital discharge and week 4 were similar between groups (see Data Supplement). There were no significant changes in urinary sodium or potassium excretion between discharge and week 4 in either group (see The baseline KCCQ summary score was similar to other previously reported cohorts at hospital discharge 20 and was not statistically different between groups (P=0.38). This was also the case with the KCCQ clinical summary score (P=0.70). The KCCQ results are illustrated in Figure 2 . The KCCQ summary score increased in both groups from hospital discharge to week 4 (DASH/SRD: 46±23-59±20, change 13±19; usual care: 43±19-53±24, change 10±16; both P<0.001). The mean increase in KCCQ summary score was 3 points greater in the DASH/SRD group, but this difference was not statistically significant (P=0.37). The KCCQ clinical summary score also increased in both groups from hospital discharge to week 4 (DASH/SRD: 47±22-65±19, change 18±20; usual care: 45±20-55±26, change 10±18; both P<0.001). The mean increase in the KCCQ clinical summary score was 9 points greater in the DASH/SRD group, nearing but not achieving statistical significance (P=0.053). Results were similar in patients with left ventricular ejection fraction <50% versus ≥50% (Figure in the Data Supplement).
There were no deaths during the first 30 days postdischarge. In the DASH/SRD group at this time point, 4 all-cause rehospitalizations had occurred in 4 patients, as compared to 12 total all-cause hospitalizations in 9 participants in the usual care group (P=0.12). During the same timeframe, in the DASH/SRD group, 3 patients had 3 HF rehospitalizations, as compared to 9 patients with a total of 11 HF rehospitalizations in the usual care group (P=0.055). Within the first 30 postdischarge days, the DASH/SRD group spent 17 cumulative days rehospitalized, as compared to 55 cumulative days in the usual care group (P=0.06 for between-group comparison after log-transformation of days hospitalized). This relationship, along with a Kaplan-Meier curve showing the probability of avoiding hospitalization or death over time since index hospital discharge is shown in Figure 3A and 3B. By 12 weeks postdischarge, 11 DASH/SRD patients had 15 total all-cause rehospitalizations, whereas 14 usual care patients had a total of 22 all-cause hospitalizations and 1 death (P=0.45 for comparison). At 12 weeks, there Values expressed as percentage, mean±SD, or median (interquartile range) for log-transformed variables. BMI indicates body mass index; BNP, B-type natriuretic peptide; DASH/SRD, sodium-restricted Dietary Approaches to Stop Hypertension eating pattern; eGFR, estimated glomerular filtration rate; and hs-troponin I, high-sensitivity troponin I.
*Statistical tests were performed on the log scale for BNP and hs-tropopnin I because of skewness.
were 8 HF rehospitalizations in 7 DASH/SRD patients, as compared to 18 HF rehospitalizations in 13 usual care patients (P=0.11). Changes in safety measures and serological biomarkers over the 4-week intervention period in participants with paired samples at both time points are shown in Table 3 . There were no significant changes in serum potassium, serum creatinine, or systolic blood pressure between discharge and week 4 in either group. BNP levels were elevated, as expected in this cohort, and increased from baseline to week 4 in the DASH/SRD group although not changing in the usual care group. High-sensitivity troponin I decreased from baseline to week 4 in the DASH/SRD group, but not in the usual care group. Prealbumin levels increased in both groups; C-reactive protein levels decreased significantly in the control group but not in the DASH/SRD cohort. There were no significant between-group changes in any of these parameters between discharge and week 4.
Three potentially diet-related adverse events occurred in the DASH/SRD group within the first 30 days postdischarge (1 each of presyncope, acute renal insufficiency, and hyperkalemia) and zero such events in the usual care group (P=0.24 for comparison by Fisher exact test). None of the events directly resulted in rehospitalization. The presyncopal episode occurred during an upper respiratory infection, and rapid heart rate was noted on home blood pressure monitoring. The participant sought medical attention 3 days later and was hospitalized for atrial fibrillation with rapid ventricular response. These events were judged unlikely to be related to diet. The acute renal insufficiency event was noted on postdischarge day 1 in a participant who was seen for concern of dehydration. The patient had not yet received study meals. Loop diuretics were discontinued, angiotensin-converting enzyme inhibitor was temporarily held, and renal function returned to baseline 2 days later. The hyperkalemia episode was identified at the week 1 safety visit and treated in the emergency department. The intervention was stopped by the blinded site primary investigator. After review of the event, the patient had been randomized to meals but mistakenly not been assigned by the study team to the lower-potassium version of DASH/SRD. 
DISCUSSION
The GOURMET-HF study is the first randomized trial to evaluate the safety and efficacy of home-delivered DASH/SRD meals postdischarge from HF hospitalization. Home delivery of meals was feasible, participants largely adhered to the study diet, and dietrelated adverse events were uncommon. Although not meeting its primary outcome, this pilot study demonstrated trends for efficacy in several domains important to recently hospitalized patients with HF and their providers. These outcomes included symptoms and physical limitations related to HF, as well as rehospitalization burden.
Most previous dietary interventions in patients with HF have focused on sodium restriction as the primary intervention. In a series of such studies performed by Italian investigators, patients with HF and reduced ejection fraction were assigned at hospital discharge to dietitian-guided moderate versus intensive sodium restriction (120 versus 80 mmol or 2800 versus 1800 mg/d) at hospital discharge. Contrary to initial expectations, patients assigned to lower sodium intake had higher readmission and mortality rates. 8, 21 These concerning findings were reinforced by the HART (Heart Failure Adherence and Retention Trial). In HART, 902 US patients with HF randomized to self-management counseling versus usual care self-reported their sodium intake with a questionnaire. After propensity-matching, patients with estimated sodium intake <2500 mg/d had a 44% higher risk of HF hospitalization. 7 One possible reason for these results would be if dietary sodium restriction compromises overall nutritional status, an aspect not considered in the studies above. When assessed with validated screening instruments, the prevalence of malnutrition in patients hospitalized for HF is at least 15% and is up to 90% in patients with advanced HF. Malnourishment has significant clinical consequences in hospitalized patients with HF, increasing length of stay and readmission rate while approximately tripling long-term mortality. [22] [23] [24] In addition, malnutrition contributes to and overlaps with frailty, sarcopenia, and reduced mobility, each individually associated with poor outcomes in patients with HF. [25] [26] [27] [28] National survey data indicate that the correlation between sodium and calorie intake is ≈0.7 in most US populations. 29 The substantially higher correlation in GOURMET-HF implies that patients with HF attempting to restrict sodium may consume insufficient calories for daily energy needs. Wellintentioned sodium restriction may also inadvertently contribute to micronutrient deficiencies in patients with HF, 9 another risk factor for poor outcomes. 30 When compared with healthy older adults, patients with HF have additional factors affecting food intake and hence nutritional status. Mobility limitations, transportation difficulties, economic concerns, and symptoms, such as dyspnea, nausea, anxiety, depression, and fatigue can greatly impact the motivation and ability to follow healthy eating patterns. 10, 31 We hypothesized that home delivery of DASH/SRD meals during the particularly vulnerable postdischarge period 4 could overcome some of these challenges. The results of the GOURMET-HF pilot *Statistical tests were performed on the log scale for BNP and hs-troponin I and on the log(x+1) scale for C-reactive protein; all transformations were made because of skewness. Estimates are presented on the percent scale (approximate percent scale for C-reactive protein). Because CIs are asymmetrical and thus SEs are not useful, we present 95% CIs for estimates: BNP (−25% lower to 55% higher); hs-troponin I (43% lower to 14% higher); and C-reactive protein (29% lower, 162% higher). study suggest that this strategy is feasible and associated with a low rate of adverse events. Overall, there was no significant change in blood pressure, serum creatinine, or serum potassium in either group. In contrast to prior studies of sodium restriction postdischarge, we did not observe progressive neurohormonal activation or azotemia. 21 This may be because medical therapy in GOURMET-HF was guided by clinical status rather than a standardized protocol or could be related to the relatively short duration of the DASH/SRD intervention.
The GOURMET-HF study was not powered or intended to determine the effect of home-delivered meals on readmission rates. However, the trend toward fewer 30-day HF readmissions and total days rehospitalized in the DASH/SRD group is encouraging. These findings are consistent with previous literature both in plausibility and magnitude. In particular, the PICNIC study (Nutritional Intervention Program in Hospitalised Patients With Heart Failure Who Are Malnourished) provides important context. The PICNIC study randomized 120 patients discharged from HF hospitalization at 2 large Spanish hospitals to an intensive, team-based 6-month nutritional intervention versus usual care. At 12 months postdischarge, the combined mortality and HF rehospitalization in the nutritional intervention group was substantially lower (27% versus 61%; P<0.001). These results were consistent across key subgroups, and the number needed to treat was 2.5 to prevent 1 event; the survival curves began to separate within the first 30 days postdischarge and continued to diverge throughout the 6-month intervention period. 32 The Kaplan-Meier curves in GOURMET-HF ( Figure 3A ) diverge during the meal delivery period, but converge after this period, suggesting that a longer intervention might be needed for sustained benefits of nutritional support.
The GOURMET-HF results are supported by the recent MEDIT-AHF study (Mediterranean Diet in Acute Heart Failure) analysis. In this prospective cohort study, Spanish patients hospitalized for acutely decompensated HF who were more adherent to a Mediterranean diet, which shares many characteristics with DASH, had a lower risk of death and rehospitalization for HF over the subsequent 12 months. 33 Our findings are also generally aligned with large cohort studies indicating that the DASH dietary pattern is associated with reduced incidence of HF and improved long-term outcomes in HF. [34] [35] [36] The mechanisms underlying any potential benefits of postdischarge nutritional support with DASH/SRD in HF are not clear from our results. Although controversy exists, reduced sodium and increased potassium intake (as expected with DASH/SRD) have been generally associated with improved cardiovascular function and outcomes. 37 Protein-calorie malnutrition, also potentially addressed by the study diet, is a strong risk factor for death and readmission in older patients hospitalized for HF. 38, 39 We did not note a differential increase in prealbumin levels in the DASH/SRD group, but this commonly used biomarker may not be an accurate index of nutritional status during acute illness. 40 Cardiac biomarkers did not demonstrate a clear trend with BNP increasing and high-sensitivity troponin I decreasing in the DASH/SRD group and no change in either parameter in usual care patients.
Limitations
The SD of the between-group change in KCCQ summary score was more than twice as large as predicted, reducing the power of the study for its primary outcome. In addition, the magnitude of the betweengroup change in KCCQ summary score (3 points) was not in a range considered clinically significant (typically >5 points). However, the magnitude of change in the DASH/SRD group was substantially greater in the domains most likely to respond to nutritional support, that is, HF symptoms and physical limitations, and negligible in less directly related domains (general quality of life and social limitations).
In most cases, food diary records were sufficient to gauge the proportion of home-delivered meals consumed by participants assigned to DASH/SRD. We could not definitively analyze the nutrients consumed during GOUR-MET-HF participation, as some 3-day food records had inadequate detail despite prompting from study personnel. Because of this limitation, we cannot provide direct comparison between the provided meals and the diet consumed postdischarge by usual care group participants.
We hypothesized that urinary sodium would decrease, and urinary potassium would increase in the DASH/SRD group and serve as a supplementary measure of adherence but did not find any changes in these parameters. Others have found poor reproducibility of 24-hour urine electrolytes during a 1-month period in stable outpatients with HF, 41 and this issue may be compounded by diuretic dose and administration route changes before discharge in hospitalized patients.
Any small treatment trial carries the risk of important between-group differences despite randomization. Although there were no statistically significant differences in baseline characteristics, it is possible that the trend toward fewer hospitalizations relates to a lower inherent risk in the DASH/SRD cohort. Because of limited prior safety and efficacy data with the DASH diet in HF, 42, 43 we enrolled only participants with a history of systemic hypertension, the focus of most prior DASH diet studies. Although most patients with HF have a history of hypertension, our findings may not be generalizable to patients who do not have a history of hypertension.
The GOURMET-HF results are hypothesis-generating and establish the rationale for conducting a larger study of direct dietary support in patients with HF after hospital discharge. Such a trial would ideally be powered to assess this strategy's impact on hospital readmission burden. In
